Log in
Enquire now
‌

US Patent 11306077 Compounds, compositions and methods

Patent 11306077 was granted and assigned to Denali Therapeutics on April, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Denali Therapeutics
Denali Therapeutics
Current Assignee
Denali Therapeutics
Denali Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11306077
Date of Patent
April 19, 2022
Patent Application Number
17334587
Date Filed
May 28, 2021
Patent Citations
‌
US Patent 10343981 Modulators of the eIF2alpha pathway
Patent Citations Received
‌
US Patent 11958840 Compounds, compositions and methods
0
Patent Primary Examiner
‌
Kahsay Habte
CPC Code
‌
C07D 417/04
‌
C07D 493/08
‌
C07D 417/14
‌
C07D 413/14
‌
C07D 271/113
‌
C07D 413/04

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11306077 Compounds, compositions and methods

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.